Johnson and Johnson Closes USD 3.4bn Acquisition of Auris Health, Expanding Digital Surgery Portfolio.
4 April 2019 - US-based healthcare company Johnson and Johnson's (NYSE: JNJ) Ethicon, Inc. business has closed the acquisition of robotic technologies developer Auris Health, Inc. for approximately USD 3.4bn in cash, the company said.
Additional contingent payments of up to USD 2.35bn, in the aggregate, may be payable upon reaching certain predetermined milestones.
Auris Health is a privately held developer of robotic technologies, initially focused in lung cancer, with an FDA-cleared platform currently used in bronchoscopic diagnostic and therapeutic procedures.
This acquisition will accelerate Johnson and Johnson's entry into robotics with potential for growth and expansion into other interventional applications.
With this acquisition, Frederic Moll, M.D., CEO and founder of Auris Health and a visionary in the field of surgical robotics, will be joining Johnson and Johnson upon completion of this transaction.
Ethicon, Inc. is a subsidiary of Johnson and Johnson. It was incorporated as a separate company under the Johnson and Johnson umbrella in 1949 to expand and diversify the Johnson and Johnson product line. Ethicon has manufactured surgical sutures and wound closure devices since 1887.
Target: Auris Health, Inc
Buyer: Johnson and Johnson/ Ethicon
Deal size in USD: 3.4bn
Type: Corporate Acquisition
Buyer advisor: , ,
|Printer friendly Cite/link Email Feedback|
|Publication:||M & A Navigator|
|Date:||Apr 4, 2019|
|Previous Article:||The Jordan Company Acquires US Manufacturer Arch Global Precision.|
|Next Article:||Horizon North Logistics Closes Acquisition of Modular Construction Provider NRB Canada.|